Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

BSH 2022 and Lymphoma View overview page

7:50
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more
Andrew Davies et al. • 4 Apr 2022
2:24
The treatment and management of PTLD
Sridhar Chaganti • 4 Apr 2022
2:32
Updates from the AVENuE trial: avelumab for advanced classical HL
Graham Collins • 3 Apr 2022
4:01
First- and second-line treatment in DLBCL
Sridhar Chaganti • 4 Apr 2022
1:46
COVID-19 vaccine effectiveness in transplant patients
Keith Wilson • 4 Apr 2022
1:27
European Society of Cardiology: 2022 cardio-oncology guidelines
Alex Lyon • 3 Apr 2022
2:28
Recent updates from ECHELON-1 and implications for the treatment of HL
Graham Collins • 3 Apr 2022
2:55
Updates from ZUMA-7: axi-cel for R/R DLBCL
Sridhar Chaganti • 4 Apr 2022
2:28
Treatment approaches for patients with R/R DLBCL: UK perspective
Wendy Osborne • 3 Apr 2022
2:47
Hodgkin lymphoma updates in the UK: ECHELON-1
Wendy Osborne • 3 Apr 2022
6:33
New data on DLBCL in the UK and its impact on treatment decisions
Wendy Osborne • 3 Apr 2022
2:07
Using prehabilitation to improve patient outcome post-transplant
Keith Wilson • 4 Apr 2022
1:38
Managing post-transplant complications in patients with DLBCL
Keith Wilson • 4 Apr 2022
0:58
Improving second-line treatments in DLBCL
Keith Wilson • 4 Apr 2022
2:52
Can we offer a curative treatment to transplant-ineligible R/R DLBCL patients?
Wendy Osborne • 3 Apr 2022
1:12
The recent FDA approval of cilta-cel and its impact on myeloma patients in the UK
Karthik Ramasamy • 3 Apr 2022
The content of VJHemOnc is intended for healthcare professionals